Anixa Biosciences, Inc.(NASDAQ : ANIX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||1.88%||553.68||2.7%||$427.43m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.48%||6.11||0.7%||$427.11m|
|GILD||Gilead Sciences, Inc.||1.59%||66.95||1.0%||$414.33m|
|XLRN||Acceleron Pharma, Inc.||0.27%||173.46||5.3%||$363.41m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.59%||183.68||1.9%||$262.38m|
|XENE||Xenon Pharmaceuticals, Inc.||-0.81%||30.47||0.4%||$170.35m|
|CRSP||CRISPR Therapeutics AG||4.56%||100.60||0.6%||$161.25m|
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the bodyâ€™s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the bodyâ€™s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patientâ€™s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.